APASL B型肝炎病毒感染在中国的西部地区

StephenW

> Hepatitis B Virus Infection in Western Region of China - see attached full poster report
>  

>
> Reported by Jules Levin
>
> APASL 2013 Singapore June 6-10
>  
>
> Yongtao SUN
>
> Tangdu Hospital, Affiliated to the Fourth Military Medical University, Xi’An, China
>  
>
> CONCLUSION
>
> Our study demonstrates that nearly half of the HBV infected patients were not being treated with antiviral agents . Most of the patients with antiviral treatment received NA therapy, Adefovir Dipivoxil was the most common used agents. The virological response rate is lower than expected. For achieve better treatment target, initiated antiviral treatment should be optimized and patient’s adherence should be improved.
>
> ABSTRACT
>
> [Background/Aims] To describe disease management in patients with Hepatitis B Virus (HBV) infection in west region of China.
>
> [Methods] A multicenter cross-sectional study of HBV or Hepatitis C Virus (HCV) infected patients was conducted during 15/08/2011 to 22/11/2011 at 10 hospitals , data was collected on the day of visit from medical records and interview of patients. For this abstract, patients with HBV mono-infection were analyzed.
>
> [Results] 4010 patients were enrolled in this study, 2561 had HBV monoinfection. The mean age was 38 years with 66.2% of males and 7.5 years of median infection duration, 12% of patients had hepatic cirrhosis.
>
> HBeAg and HBeAb were positive in 45.4 % and 50.5% respectively.
>
> The antiviral treatment rate was 58%, among the patients with current or most recent antiviral therapy data, 86% received nucleoside/nucleotide analogues(NA), 9% received interferon or pegylated interferon(INF), 5% received combination therapy of NA and INF.
>
> In the patients with antiviral evaluation, 80.5% had virological response, 13.1% had HBeAg loss/seroconversion (102) or HBsAg loss/seroconversion (4). Traditional Chinese Medicine including herbs was the most frequently used alternate treatment.
>

StephenW

永涛SUN
>
>唐都医院，第四军医大学附属西安，中国
>
>
>结论
>
我们的研究表明，近一半的乙肝病毒感染患者没有得到治疗与抗病毒药物。阿德福韦酯抗病毒治疗的大多数患者接受NA治疗，是最常用的代理。病毒学应答率低于预期。为了达到更好的治疗目标，启动抗病毒治疗应优化，并应提高患者的依从性。
>
>摘要
>
>[背景/目的]为了描述患者的疾病管理与乙型肝炎病毒（HBV）感染在中国的西部地区。
>
>[方法]的多中心横断面研究乙型肝炎病毒或丙型肝炎病毒（HCV）感染患者在10家医院进行15/08/2011至22/11/2011期间，参观当日病历数据收集患者和面试。对于这个抽象的，HBV单一感染的患者进行了分析。
>
[结果]4010例患者参加了这项研究，2561年有HBV单一感染。平均年龄为38岁，66.2％的男性和7.5年的中位数持续感染，12％的患者有肝硬化。
>
> HBeAg和HBeAb的阳性分别为45.4％和50.5％。
>
>抗病毒治疗率为58％，与当前或最近的抗病毒治疗数据的患者中，86％的患者接受核苷/核苷酸类似物（NA），9％，5％接受干扰素或聚乙二醇干扰素（INF）联合治疗NA和INF。
>
>在患者抗病毒药评价，80.5％，13.1％HBeAg阴转/血清学转换（102）或HBsAg消失/血清学转换（4）的病毒学应答。中国传统医药包括草药是最常用的替代治疗。